NeoGenomics to Report Second Quarter 2024 Financial Results on July 29, 2024

Rhea-AI Summary

NeoGenomics (NASDAQ: NEO), a premier oncology testing services company, will release its Q2 2024 financial results on July 29, 2024, after U.S. markets close. A webcast and conference call to discuss the financial outcomes and recent highlights are scheduled for 4:30 p.m. ET the same day. Interested parties can access the live webcast through the Investor Relations section on NeoGenomics' website, with a replay available afterward. For phone access, dial (888) 506-0062 (domestic) or (973) 528-0011 (international) using the participant code 276062.

Positive

• None.

FT. MYERS, Fla.--(BUSINESS WIRE)-- NeoGenomics, Inc. (NASDAQ: NEO), a leading oncology testing services company, today announced that it will report its second quarter 2024 financial results after the close of the U.S. financial markets on Monday, July 29, 2024. Company management will host a webcast and conference call at 4:30 p.m. ET to discuss financial results and recent highlights.

The live webcast may be accessed by visiting the Investor Relations section of our website at ir.neogenomics.com. The webcast will be archived and available for replay shortly after the conclusion of the call.

To access the live call via telephone, dial (888) 506-0062 (domestic) or (973) 528-0011 (international) at least five minutes prior to the call. The participant access code is 276062.

About NeoGenomics, Inc.

NeoGenomics, Inc. specializes in cancer genetics testing and information services, providing one of the most comprehensive oncology-focused testing menus in the world for physicians to help them diagnose and treat cancer. The Company's Pharma Services Division serves pharmaceutical clients in clinical trials and drug development.

Headquartered in Fort Myers, FL, NeoGenomics operates CAP accredited and CLIA certified laboratories for full-service sample processing in Fort Myers, Florida; Aliso Viejo and San Diego, California; Research Triangle Park, North Carolina; and Houston, Texas; and a CAP accredited full-service, sample-processing laboratory in Cambridge, United Kingdom. NeoGenomics also has several, small, non-processing laboratory locations across the United States for providing analysis services. NeoGenomics serves the needs of pathologists, oncologists, academic centers, hospital systems, pharmaceutical firms, integrated service delivery networks, and managed care organizations throughout the United States, and pharmaceutical firms in Europe and Asia.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240709121031/en/

Investor Contact

Kendra Sweeney

kendra.sweeney@neogenomics.com

Media Contact

Andrea Sampson

asampson@sampsonprgroup.com

Source: NeoGenomics, Inc.

FAQ

When will NeoGenomics release its Q2 2024 financial results?

NeoGenomics will release its Q2 2024 financial results on July 29, 2024, after the U.S. financial markets close.

How can I listen to NeoGenomics' Q2 2024 earnings call?

You can listen to the Q2 2024 earnings call via webcast on the Investor Relations section of NeoGenomics' website or by dialing (888) 506-0062 (domestic) or (973) 528-0011 (international) using the participant code 276062.

What time is NeoGenomics' Q2 2024 earnings call?

The NeoGenomics Q2 2024 earnings call is scheduled for 4:30 p.m. ET on July 29, 2024.

Where can I find the replay of NeoGenomics' Q2 2024 earnings call?

The replay of NeoGenomics' Q2 2024 earnings call will be available shortly after the live webcast concludes, accessible through the Investor Relations section of their website.